Biologics Supplier for Medspas and Dermatology Clinics in Lancaster, PA

Physician Supervision and Account Eligibility

Medspas are not treated differently from any other licensed buyer, but account verification for a medspa generally ties to the NPI of the supervising or medical director physician rather than the business entity itself. Dermatology and plastic surgery practices typically register under the treating physician's own NPI.

A medspa opening its first account should confirm which physician's NPI will anchor the account before submitting a request.

What a Vendor File Usually Contains

Dermatology practices, plastic surgery practices, and medspas that already purchase other injectable or topical products from regulated suppliers tend to apply a similar standard to a biologics vendor: confirmation of HCT/P registration status, donor screening and testing descriptions, and a sample certificate of analysis before the first order.

Smaller single-physician medspas may complete this review more quickly than multi-location dermatology groups, which often route the file through a compliance or office manager first.

Receiving and Storing Shipments

Cryopreserved Wharton's jelly formats ship overnight on dry ice and need storage at -80 degrees C on arrival, so a practice should confirm freezer capacity before the first order ships. Lyophilized exosome products are shelf-stable under normal storage conditions per the supplier and do not require a cryogenic freezer, which many medspas find easier to accommodate.

Documentation and Regulatory Verification

Each lot ships with a unique identifier, and a certificate of analysis and donor eligibility summary are available to verified accounts on request. Wharton's jelly products are offered under the supplier's HCT/P framework; whether a given use qualifies under 21 CFR 1271.10 is a determination for the practice and its counsel, not for Precision Biologics.

Exosome products are not FDA approved and are generally regulated as biologic drugs. Medspas and dermatology practices should verify their intended use with their medical director and with the Pennsylvania State Board of Medicine before purchasing.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.